163 related articles for article (PubMed ID: 9641543)
1. Effects of pravastatin on cholesterol metabolism of cholesterol-fed heterozygous WHHL rabbits.
Harsch M; Gebhardt A; Reymann A; Lang G; Schliack M; Löser R; Braesen JH; Niendorf A
Br J Pharmacol; 1998 May; 124(2):277-82. PubMed ID: 9641543
[TBL] [Abstract][Full Text] [Related]
2. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
[TBL] [Abstract][Full Text] [Related]
3. Hepatic cholesterol and bile acid synthesis, low-density lipoprotein receptor function, and plasma and fecal sterol levels in mice: effects of apolipoprotein E deficiency and probucol or phytosterol treatment.
Moghadasian MH; Nguyen LB; Shefer S; Salen G; Batta AK; Frohlich JJ
Metabolism; 2001 Jun; 50(6):708-14. PubMed ID: 11398149
[TBL] [Abstract][Full Text] [Related]
4. Serum noncholesterol sterols in children with heterozygous familial hypercholesterolemia undergoing pravastatin therapy.
Hedman M; Miettinen TA; Gylling H; Ketomäki A; Antikainen M
J Pediatr; 2006 Feb; 148(2):241-6. PubMed ID: 16492436
[TBL] [Abstract][Full Text] [Related]
5. [Effect of pravastatin on hepatic cholesterol metabolism].
Reihnér E; Rudling M; Ståhlberg D; Berglund L; Ewerth S; Björkhem I; Einarsson K; Angelin B
Fortschr Med; 1991 Mar; 109(8):189-94. PubMed ID: 1905265
[TBL] [Abstract][Full Text] [Related]
6. Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin.
Thelen KM; Rentsch KM; Gutteck U; Heverin M; Olin M; Andersson U; von Eckardstein A; Björkhem I; Lütjohann D
J Pharmacol Exp Ther; 2006 Mar; 316(3):1146-52. PubMed ID: 16282522
[TBL] [Abstract][Full Text] [Related]
7. Regulation of hepatic cholesterol metabolism in CETP/LDLr mice by cholesterol feeding and by drugs (cholestyramine and lovastatin) that lower plasma cholesterol.
Harada LM; Carrilho AJ; Oliveira HC; Nakandakare ER; Quintão EC
Clin Exp Pharmacol Physiol; 2006 Dec; 33(12):1209-15. PubMed ID: 17184503
[TBL] [Abstract][Full Text] [Related]
8. Effect of fluvastatin sodium on the smooth muscle cells in atherosclerotic plaques. In vivo study using low-density lipoprotein receptor deficient Watanabe heritable hyperlipidemic (WHHL) rabbits.
Shiomi M; Ito T; Tsukada T; Shiraishi M; Yata T
Arzneimittelforschung; 1998 Jun; 48(6):680-5. PubMed ID: 9689427
[TBL] [Abstract][Full Text] [Related]
9. Effect of fluvastatin sodium on secretion of very low density lipoprotein and serum cholesterol levels. In vivo study using low density lipoprotein receptor deficient watanabe heritable hyperlipidemic rabbits.
Shiomi M; Shiraishi M; Yata T; Ito T
Arzneimittelforschung; 1994 Oct; 44(10):1154-6. PubMed ID: 7818592
[TBL] [Abstract][Full Text] [Related]
10. Experimental model of escape phenomenon in hamsters and the effectiveness of YM-53601 in the model.
Ugawa T; Kakuta H; Moritani H; Shikama H
Br J Pharmacol; 2002 Mar; 135(6):1572-8. PubMed ID: 11906972
[TBL] [Abstract][Full Text] [Related]
11. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.
Reihnér E; Rudling M; Ståhlberg D; Berglund L; Ewerth S; Björkhem I; Einarsson K; Angelin B
N Engl J Med; 1990 Jul; 323(4):224-8. PubMed ID: 2114543
[TBL] [Abstract][Full Text] [Related]
12. The mechanism of comparable serum cholesterol lowering effects of pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A inhibitor, between once- and twice-daily treatment regimens in beagle dogs and rabbits.
Fujioka T; Nara F; Shimada Y; Fukushige J; Shimotsu H; Shigehara E; Fukami M; Tsujita Y
Jpn J Pharmacol; 1996 Apr; 70(4):329-35. PubMed ID: 8774761
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the antiatherosclerotic effects of dihydropyridine calcium channel blocker and HMG-CoA reductase inhibitor on hypercholesterolemic rabbits.
Takayama M; Matsubara M; Arakawa E; Takada C; Ina Y; Hasegawa K; Yao K
Vascul Pharmacol; 2007 Apr; 46(4):302-8. PubMed ID: 17197250
[TBL] [Abstract][Full Text] [Related]
14. Fluvastatin prevents renal injury and expression of lactin-like oxidized low-density lipoprotein receptor-1 in rabbits with hypercholesterolemia.
Yu YH; Wang Y; Dong B; Sun SZ; Chen Y; Meng XH; Liu ZZ
Chin Med J (Engl); 2005 Apr; 118(8):621-6. PubMed ID: 15899115
[TBL] [Abstract][Full Text] [Related]
15. Effects of plant stanol and sterol esters on serum phytosterols in a family with familial hypercholesterolemia including a homozygous subject.
Ketomaki A; Gylling H; Miettinen TA
J Lab Clin Med; 2004 Apr; 143(4):255-62. PubMed ID: 15085084
[TBL] [Abstract][Full Text] [Related]
16. [Effects of pravastatin on hepatic plasminogen activator inhibitor 1 mRNA expression in rabbits with fatty liver].
Fan J; Chen L; Zeng M
Zhonghua Gan Zang Bing Za Zhi; 2000 Apr; 8(2):70-2. PubMed ID: 10861105
[TBL] [Abstract][Full Text] [Related]
17. HMG-CoA reductase inhibitor augments the serum total cholesterol-lowering effect of human adipose tissue-derived multilineage progenitor cells in hyperlipidemic homozygous Watanabe rabbits.
Saga A; Okura H; Soeda M; Tani J; Fumimoto Y; Komoda H; Moriyama M; Moriyama H; Yamashita S; Ichinose A; Daimon T; Hayakawa T; Matsuyama A
Biochem Biophys Res Commun; 2011 Aug; 412(1):50-4. PubMed ID: 21806964
[TBL] [Abstract][Full Text] [Related]
18. [Pravastatin increases the activity pf the LDL receptors in lymphocytes of individuals with heterozygous familial hypercholesterolemia].
Alvarez-Sala LA; Mata P; Blázquez E; Garrido JA; Ordovás JM; Rubio MJ; de Oya M
Rev Clin Esp; 1997 May; 197(5):317-22. PubMed ID: 9280964
[TBL] [Abstract][Full Text] [Related]
19. The pravastatin-induced decrease of biliary cholesterol secretion is not directly related to an inhibition of cholesterol synthesis in humans.
Kallien G; Lange K; Stange EF; Scheibner J
Hepatology; 1999 Jul; 30(1):14-20. PubMed ID: 10385633
[TBL] [Abstract][Full Text] [Related]
20. The effect of pravastatin in relation to low density lipoprotein receptor activity.
Hayashi H; Naito C; Ito H; Kawamura M; Miyazaki S
Curr Med Res Opin; 1990; 12(2):100-7. PubMed ID: 2118022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
